Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BBIO 
BridgeBio Pharma Inc (BBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: BBIO (3-star) is a STRONG-BUY. BUY since 97 days. Simulated Profits (41.38%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $65.1
1 Year Target Price $65.1
| 10 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 62.62% | Avg. Invested days 35 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.84B USD | Price to earnings Ratio - | 1Y Target Price 65.1 |
Price to earnings Ratio - | 1Y Target Price 65.1 | ||
Volume (30-day avg) 19 | Beta 1.25 | 52 Weeks Range 21.72 - 54.60 | Updated Date 09/16/2025 |
52 Weeks Range 21.72 - 54.60 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -120.72% |
Management Effectiveness
Return on Assets (TTM) -41.96% | Return on Equity (TTM) -1789.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10891213089 | Price to Sales(TTM) 41.73 |
Enterprise Value 10891213089 | Price to Sales(TTM) 41.73 | ||
Enterprise Value to Revenue 46.19 | Enterprise Value to EBITDA -9.4 | Shares Outstanding 191168992 | Shares Floating 151355751 |
Shares Outstanding 191168992 | Shares Floating 151355751 | ||
Percent Insiders 4.77 | Percent Institutions 101.55 |
Upturn AI SWOT
BridgeBio Pharma Inc
Company Overview
History and Background
BridgeBio Pharma, Inc. was founded in 2015 to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. It focuses on identifying and developing therapies for Mendelian diseases and genetically defined cancers.
Core Business Areas
- Genetic Disease Drug Development: Focuses on developing therapies for rare genetic diseases with high unmet medical need. This includes research and clinical trials for specific genetic disorders.
- Genetically Defined Cancer Drug Development: Developing targeted therapies for cancers that are driven by specific genetic mutations or alterations. This involves identifying cancer-causing genes and developing drugs that specifically target these genes.
Leadership and Structure
Neil Kumar serves as the CEO. The organizational structure consists of various departments including research and development, clinical operations, regulatory affairs, and commercial functions, all guided by a board of directors.
Top Products and Market Share
Key Offerings
- NULIBRY (fosdenopterin): NULIBRY is approved for the treatment of Molybdenum Cofactor Deficiency (MoCD) Type A, a rare genetic disorder. While specific market share data is limited, it is the only approved therapy for this ultra-rare disease. Competitors include companies researching gene therapies or alternative treatments for MoCD Type A, though no direct competitors currently have approved products.
- Truseltiq (infigratinib): Truseltiq is approved for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 fusion or rearrangements. Competitors in the FGFR inhibitor market include Pemazyre by Incyte.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and regulatory scrutiny. The market for rare disease therapies is growing, driven by increasing awareness, orphan drug designations, and unmet medical needs.
Positioning
BridgeBio is positioned as a company focused on developing therapies for genetically defined diseases. Its competitive advantage lies in its focus on precision medicine and its ability to identify and develop therapies for rare and underserved patient populations.
Total Addressable Market (TAM)
The TAM for therapies targeting genetic diseases and genetically defined cancers is estimated to be substantial, potentially reaching tens of billions of dollars annually. BridgeBio is positioned to capture a significant portion of this market by developing and commercializing novel therapies for specific genetic disorders and cancer subtypes.
Upturn SWOT Analysis
Strengths
- Strong focus on genetically defined diseases
- Deep pipeline of potential therapies
- Experienced management team
- Strategic partnerships with academic institutions and other biopharmaceutical companies
Weaknesses
- High cash burn rate
- Reliance on clinical trial success
- Limited commercial infrastructure
- Dependence on key partnerships
Opportunities
- Expansion into new therapeutic areas
- Acquisition of complementary technologies or companies
- Accelerated regulatory pathways for rare disease therapies
- Increasing prevalence of genetic testing and diagnosis
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from larger pharmaceutical companies
- Pricing pressures for orphan drugs
Competitors and Market Share
Key Competitors
- INCY
- BMY
- GILD
- REGN
- VRTX
Competitive Landscape
BridgeBio competes with both large pharmaceutical companies and smaller biotechnology companies in the rare disease and cancer therapy markets. Its competitive advantage lies in its focus on genetically defined diseases and its ability to identify and develop therapies for underserved patient populations. However, it faces competition from companies with greater resources and more established commercial infrastructure.
Major Acquisitions
Eidos Therapeutics
- Year: 2021
- Acquisition Price (USD millions): 3000
- Strategic Rationale: Acquisition of Eidos Therapeutics strengthens BridgeBio's pipeline with a late-stage therapy for transthyretin amyloidosis (ATTR).
Growth Trajectory and Initiatives
Historical Growth: BridgeBio's historical growth has been driven by the advancement of its pipeline and strategic acquisitions. The company's revenue growth is dependent on product approvals and commercialization.
Future Projections: Future growth is projected to be driven by the successful development and commercialization of its pipeline therapies. Analyst estimates vary based on the company's clinical trial results and regulatory milestones.
Recent Initiatives: Recent initiatives include advancing key clinical trials, expanding partnerships, and exploring new therapeutic areas.
Summary
BridgeBio is a focused biopharmaceutical company targeting genetic diseases and cancers, showing promise in precision medicine. Its pipeline and strategic acquisitions are significant, but high cash burn and clinical trial dependence are risks. Future success relies on pipeline advancement and navigating competitive pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be subject to change. Market share data is an estimate and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BridgeBio Pharma Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2019-06-27 | Co-Founder, CEO & Director Dr. Neil Kumar Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 725 | Website https://bridgebio.com |
Full time employees 725 | Website https://bridgebio.com | ||
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.